All COVID-19 Clinical Research Coalition members were invited to come together to take stock of our successes and challenges and to contribute to a discussion of the Coalition’s evolving future.

In this webinar experts and members of the Therapeutics Working Group discussed the current status of COVID-19 therapeutics, availability of these expensive medicines in low-resource settings, and research needs to advise and guide health policies.

In this webinar experts and members of the Data Sharing Working Group shared initiatives to promote effective, equitable, and efficient data sharing for COVID-19 clinical research.

In this webinar experts and members of the Clinical Epidemiology Working Group discussed the preparedness and challenges of LMICs to attend patients with post-COVID-19 condition.

Following the coalition’s efforts to increase the representation of researchers from low- and middle-income countries in the ACT-Accelerator Therapeutics Partnership, four coalition members have joined its workstreams. Meet Dr Sauman Singh, from DNDi and IDDO, India, who joined workstream 2.

Where are we today with new and emerging therapeutics that would be both effective and affordable in preventing the progression of mild or moderate COVID-19 and thereby prevent hospitalization? A couple of promising treatments have emerged recently, with early efforts underway to make these drugs more available than COVID-19 vaccines have been. What are the current research priorities, and do current efforts meet the needs? These were the key questions addressed in a recent webinar hosted by the COVID-19 Clinical Research Coalition.

Following the coalition’s efforts to increase the representation of researchers from low- and middle-income countries in the ACT-Accelerator Therapeutics Partnership, four coalition members have joined its workstreams. Meet Dr Nada Melhem, from the American University of Beirut in Lebanon, who joined workstream 1 which focuses on rapid evidence assessment of therapeutic candidates.